The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: from molecular mechanisms to clinical applications.
The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: from molecular mechanisms to clinical applications.
复制标题
DOI：
10.1016/j.phrs.2020.105031
复制
发表时间：
2020-06
影响因子：
9.3
通讯作者：
Bangyue Luo;Jiali Jiang;Yifan Fang;Fang Yang;Mengdie Yin;Bingchen Zhang;Ruirui Zhao;Jing-Wei Shao
中科院分区：
文献类型：
--
作者：
Bangyue Luo;Jiali Jiang;Yifan Fang;Fang Yang;Mengdie Yin;Bingchen Zhang;Ruirui Zhao;Jing-Wei Shao
由血小板聚集异常引发的血栓形成是大多数心血管疾病（CVD）发生之前的关键病理事件。最近，越来越多的证据表明血小板可能成为预防心血管疾病的潜在目标。然而，作为传统的抗血栓治疗策略，目前的抗血小板药物的应用受到其各种副作用的限制，例如出血风险和耐药性。因此，已经努力寻找作为补充疗法的药物。人参皂苷是从人参中提取的主要活性成分，因其对血小板聚集的多个关键事件的调节而备受关注。本文从结构特征到临床应用，剖析了人参皂苷抗血小板作用的内在结构与功能关系，并对其所涉及的信号通路进行了具体总结。此外，重点还放在研究人参皂苷在 CVD 治疗中的抗血栓功效的临床研究上。此外，还对提高人参皂苷生物利用度的方法进行了广泛的概述。还讨论了当前研究的局限性和前景。该研究可能为系统认识人参皂苷在CVD治疗中的作用提供一些新的见解，并为未来的研究奠定基础。
Thrombosis initiated by abnormal platelet aggregation is a pivotal pathological event that precedes most cases of cardiovascular diseases (CVD). Recently, growing evidence indicates that platelet could be a potential target for CVD prevention. However, as the conventional antithrombotic management strategy, applications of current antiplatelet agents are somewhat limited by their various side effects, such as bleeding risk and drug resistance. Hence, efforts have been made to search for agents as complementary therapies. Ginsenoside, the principal active component extracted fromPanax ginseng, has gained much attention for its regulations on multiple crucial events of platelet aggregation. From structural characteristics to clinical applications, this review anatomized the intrinsic structure-function relationship of antiplatelet potency of ginsenosides, and the involved signal pathways were specifically summarized. Additionally, the emphasis was placed on clinical studies that investigate the antithrombotic efficacy of ginsenosides in the treatment of CVD. Further, a broad overview of approaches for improving the bioavailability of ginsenosides was concluded. Limitations and prospects of current studies were also discussed. This study may provide some new insights into the systematic understanding of ginsenosides in CVD treatment and lay a foundation for future research.